{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:37:57Z","timestamp":1789641477379,"version":"4.0.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T00:00:00Z","timestamp":1484784000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40261-017-0492-5","type":"journal-article","created":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T07:59:20Z","timestamp":1484812760000},"page":"317-326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["US FDA Perspective on Elbasvir\/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5859-7722","authenticated-orcid":false,"given":"Sarita D.","family":"Boyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaRee","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi E.","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabha","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sherwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,19]]},"reference":[{"key":"492_CR1","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter Suppl. 2013;3:1\u2013150."},{"issue":"2","key":"492_CR2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","volume":"139","author":"AS Levey","year":"2003","unstructured":"Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137\u201347.","journal-title":"Ann Intern Med."},{"issue":"1","key":"492_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M15-0785","volume":"163","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1\u201313. doi: 10.7326\/M15-0785 .","journal-title":"Ann Intern Med."},{"issue":"8","key":"492_CR4","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","volume":"2","author":"JK Rockstroh","year":"2015","unstructured":"Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319\u201327. doi: 10.1016\/S2352-3018(15)00114-9 .","journal-title":"Lancet HIV."},{"issue":"10003","key":"492_CR5","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537\u201345. doi: 10.1016\/S0140-6736(15)00349-9 .","journal-title":"Lancet."},{"issue":"3","key":"492_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","volume":"63","author":"X Forns","year":"2015","unstructured":"Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63(3):564\u201372. doi: 10.1016\/j.jhep.2015.04.009 .","journal-title":"J Hepatol."},{"issue":"1","key":"492_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/cid\/civ722","volume":"62","author":"M Buti","year":"2016","unstructured":"Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-Week results from C-SALVAGE. Clin Infect Dis. 2016;62(1):32\u20136. doi: 10.1093\/cid\/civ722 .","journal-title":"Clin Infect Dis."},{"issue":"9973","key":"492_CR8","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"E Lawitz","year":"2015","unstructured":"Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12\u00a0weeks versus 18\u00a0weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075\u201386. doi: 10.1016\/S0140-6736(14)61795-5 .","journal-title":"Lancet."},{"issue":"9973","key":"492_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"M Sulkowski","year":"2015","unstructured":"Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8\u00a0weeks versus 12\u00a0weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087\u201397. doi: 10.1016\/S0140-6736(14)61793-1 .","journal-title":"Lancet."},{"key":"492_CR10","unstructured":"Zepatier (elbasvir and grazoprevir) tablets [package insert]. Whitehouse Station, NJ: Merck & CO, Inc.; 2016"},{"issue":"1","key":"492_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77\u201387. doi: 10.1002\/hep.27259 .","journal-title":"Hepatology."},{"issue":"1 Suppl","key":"492_CR12","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45\u201357. doi: 10.1016\/j.jhep.2014.07.027 .","journal-title":"J Hepatol."},{"key":"492_CR13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.10.017","author":"TE Komatsu","year":"2016","unstructured":"Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O\u2019Rear JJ, et al. Regulatory analysis of effects of hepatitis c virus ns5a polymorphisms on efficacy of elbasvir and grazoprevir. Gastroenterology. 2016. doi: 10.1053\/j.gastro.2016.10.017 .","journal-title":"Gastroenterology."},{"key":"492_CR14","unstructured":"21CFR 201.57 (c)(2)(ii). Specific requirements on content and format of labeling for human prescription drug and biological products described in \u00a7201.56(b)(1). March 18, 2016."},{"issue":"16","key":"492_CR15","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483\u201393. doi: 10.1056\/NEJMoa1316366 .","journal-title":"N Engl J Med."},{"key":"492_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28467","author":"P Kwo","year":"2016","unstructured":"Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, et al. Simeprevir plus sofosbuvir (12 and 8\u00a0weeks) in hcv genotype 1-infected patients without cirrhosis: OPTIMIST-1, a Phase 3, randomized study. Hepatology. 2016. doi: 10.1002\/hep.28467 .","journal-title":"Hepatology."},{"key":"492_CR17","unstructured":"Trials.gov C. Study of Oral Treatments for Hepatitis C (PRIORITIZE). 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02786537 . Accessed 21 Dec 2016."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0492-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-017-0492-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0492-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T04:36:27Z","timestamp":1498365387000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-017-0492-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,19]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["492"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0492-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,19]]}}}